AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34483029
Drug: Ivermectin 12
RxNorm normalized name: Ivermectin 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 12 mg
Trial: 34483029
Drug: Ivermectin 24
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 24 mg and 12 mg
Trial: 35599913
Drug: Greek yogurt
RxNorm normalized name: Greek pitch
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greek yogurt (GY), 3 servings/day, 115 kcal, 17 g protein, 11.5 g carbohydrates
Trial: 35599913
Drug: Isoenergetic carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic carbohydrate control (CHO), 3 servings/day, 115 kcal, 0.04 g protein, 28.6 g carbohydrates
Trial: 32330277
Drug: High-dosage CQ
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage CQ (600 mg CQ twice daily for 10 days)
Trial: 32330277
Drug: Low-dosage CQ
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage CQ (450 mg twice daily on day 1 and once daily for 4 days)
Trial: 32330277
Drug: High-dosage CQ
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage CQ
Trial: 32330277
Drug: Low-dosage CQ
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage CQ
Trial: 39085664
Drug: Usual Treatment
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Treatment (UT)
Trial: 32967528
Drug: Seven daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven daily sessions of mindfulness training
Trial: 32563253
Drug: Amaranth seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amaranth seed oil (ASO) 20 mL/d
Trial: 32563253
Drug: Rapeseed oil
RxNorm normalized name: Rapeseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed oil (RSO) 20 mL/d
Trial: 32236104
Drug: Combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination
Trial: 36343646
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of hypertonic saline
Trial: 36343646
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of dornase alfa
Trial: 32594305
Drug: Oral omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral omeprazole
Trial: 33143647
Drug: Arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic microfracture with atelocollagen augmentation (group 1, n = 31)
Trial: 33143647
Drug: Arthroscopic microfracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic microfracture with atelocollagen augmentation (group 1)
Trial: 33947827
Drug: 10-week individual-based
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-week individual-based multimodal program of task-oriented exercises integrated with cognitive-behavioral therapy
Trial: 32838584
Drug: Vaccine development
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine development efforts against sexually transmitted viruses (STVs)
Trial: 32838584
Drug: Various approaches
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various approaches for improving prophylactic or therapeutic vaccines
Trial: 34021038
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rivaroxaban 2.5 mg two times per day and aspirin 100 mg once daily
Trial: 34021038
Drug: Non-study aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-study aspirin
Trial: 34670132
Drug: Algorithm-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided treatment with escitalopram (AGT-E)
Trial: 34670132
Drug: Algorithm-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided treatment with mirtazapine (AGT-M)
Trial: 32234000
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of omeprazole enteric-coated tablet 20 mg
Trial: 32234000
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of omeprazole
Trial: 34224994
Drug: High-dose IFN-β
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN-β 1a (88 μg on days 1, 3, 6) + lopinavir/ritonavir (400 mg/100 mg twice a day for 10 days)
Trial: 34224994
Drug: Low-dose IFN-β
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN-β 1a (44 μg on days 1, 3, 6) + lopinavir/ritonavir (400 mg/100 mg twice a day for 10 days)
Trial: 34224994
Drug: High-dose IFN-β
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN-β 1a
Trial: 34224994
Drug: Low-dose IFN-β
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN-β 1a
Trial: 36107972
Drug: ICE (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE (450 g of -2°C ice slurry)
Trial: 33950949
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) plus chemotherapy (Kang Ai injection, herbal decoction, Zhenqifuzheng capsules)
Trial: 33864994
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received a training booklet about chemotherapy-induced fatigue)
Trial: 34482505
Drug: Hydrogen-rich ultrapure
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich ultrapure water (HRW) 500 mg of nickel chloride kg‐1 soil for 14 days
Trial: 34482505
Drug: Hydrogen-rich ultrapure
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich ultrapure water (HRW) 200 mg of nickel chloride kg‐1 soil for 14 days
Trial: 32295442
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment
Trial: 32939556
Drug: Glycine intake
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine intake (5-100 mg·kg‐1·d‐1) during late gestation
Trial: 32939556
Drug: Glycine intake
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine intake (5-100 mg·kg‐1·d‐1) during midgestation
Trial: 34226226
Drug: Oral furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral furosemide 80 mg/day (adjusted to 160 mg/day if urine volume < 400 mL/day after 2 weeks)
Trial: 34348606
Drug: Standard evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard evidence-based therapies
Trial: 32715937
Drug: Random Forest
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random Forest (RF) classifier used to predict treatment effect perception based on primary endpoints and judges' evaluations.
Trial: 32300002
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and relaxation techniques administered by non-specialist providers, with six individual sessions and two to six booster sessions.
Trial: 32990206
Drug: Propofol monotherapy
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol monotherapy
Trial: 36114653
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester supplementation (27 g per dose, thrice daily)
Trial: 32149579
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 1,000 IU/day
Trial: 32149579
Drug: Single 200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 200,000 IU injection (equivalent to 2,000 IU/day)
Trial: 32252707
Drug: Internet-delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Acceptance and Commitment Therapy (IACT)
Trial: 32252707
Drug: Adjusting treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusting treatment content and format based on participants' characteristics
Trial: 32785986
Drug: Microneedling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling and 5-fluorouracil solution (group C)
Trial: 33568383
Drug: Roxadustat (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (70 mg oral, thrice-weekly)
Trial: 35969113
Drug: Milk oral
RxNorm normalized name: lytes/dextros/mvn/AA/ging/milk ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk oral immunotherapy (OIT)
Trial: 37125490
Drug: SA4Ag vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA4Ag vaccine
Trial: 35137458
Drug: GnRH (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH (37.5 µg of Lecirelin)
Trial: 35137458
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 mL of physiological saline solution)
Trial: 34052828
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline 100 mg bid for 8 weeks
Trial: 34981516
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (KO) - 7 capsules per day (1.27g n-3 PUFA)
Trial: 34981516
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) - 5 capsules per day (1.44g n-3 PUFA)
Trial: 33451627
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (1000 mg)
Trial: 37215391
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (NSPT)
Trial: 35876941
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml water
Trial: 36206208
Drug: Community-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based occupational therapy intervention (COT-MHABI) over one year, 16 sessions on average.
Trial: 32946836
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine candidate (0.5 mL administered intramuscularly on days 0, 7, and 30)
Trial: 32946836
Drug: Placebo vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaccine (0.5 mL administered intramuscularly on days 0, 7, and 30)
Trial: 32946836
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine candidate
Trial: 33970752
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of fast-release melatonin
Trial: 34999239
Drug: Single-dose ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ivermectin 1200 μg/kg for 5 days (arm C)
Trial: 34999239
Drug: Single-dose ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose ivermectin 600 μg/kg plus placebo for 5 days (arm B)
Trial: 36075243
Drug: Brensocatib 25
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib 25 mg once daily for 28 days
Trial: 38362600
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy
Trial: 35152573
Drug: Simple carotid
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple carotid endarterectomy (CEA) with conventional treatment (aspirin and clopidogrel)
Trial: 33059356
Drug: LSD 25
RxNorm normalized name: LSD 25
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 25 µg
Trial: 33059356
Drug: LSD 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 50 µg
Trial: 37231080
Drug: LSD 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 100 µg
Trial: 33059356
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg + LSD 200 µg
Trial: 33059356
Drug: LSD (25-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (25-200 µg)
Trial: 33188930
Drug: Hydroxychloroquine, specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine, specific dosage and duration not available
Trial: 33188930
Drug: Propensity score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propensity score methods, including g-computation and doubly robust estimators, specific details not available
Trial: 34824100
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (hs-cTnT <5 ng/L at presentation)
Trial: 34267331
Drug: Various ML
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various ML techniques (XGBoost, LightGBM, Catboost, Support vector machine (SVM), Logistic regression (LR))
Trial: 35537533
Drug: Brolucizumab 6
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab 6 mg every 4 weeks
Trial: 35537533
Drug: Aflibercept 2
RxNorm normalized name: ziv-aflibercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 2 mg every 4 weeks
Trial: 32404117
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (FiO2 = 0.6, inhaling PGE1 0.1 μg/kg)
Trial: 32404117
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P and Group L
Trial: 32404117
Drug: Group P,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P, Group L, and Group C
Trial: 33608841
Drug: Acetaminophen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,000 mg)
Trial: 36828201
Drug: Everolimus (EVL)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVL) and low-dose tacrolimus (LD-TAC)
Trial: 32951744
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage for 15 minutes daily (Group A)
Trial: 32951744
Drug: PEG 20g
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 20g daily (Group B)
Trial: 32951744
Drug: PEG 20g
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 20g plus abdominal massage for 15 minutes daily (Group C)
Trial: 35628840
Drug: Pre-emptive analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive analgesic acetaminophen (15 mg/kg)
Trial: 33831899
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg/kg bolus over 10 min followed by continuous infusion of 100 μg/kg/min)
Trial: 34980867
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid and ezetimibe combination
Trial: 33176703
Drug: Group-based multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based multicomponent high intensity exercise program led by a physiotherapist twice a week for 4 months.
Trial: 36273203
Drug: HA-VTE risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates; additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025) including recommendations for pharmacologic prophylaxis if appropriate.
Trial: 33172456
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser pre-treatment (energy 50-300 mJ, frequency 5-30 Hz)
Trial: 33172456
Drug: Conventional acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acid etching treatment
Trial: 33174761
Drug: Bare-metal stent
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare-metal stent plus 1 mg of colchicine for 3 months
Trial: 33174761
Drug: Drug-eluting stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stent alone
Trial: 35183498
Drug: Isonicotinic acid
RxNorm normalized name: Isonicotinic acid
DrugBank: Isonicotinic acid (DB16884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isonicotinic acid hydrazide (INH) 900 mg vaginally
Trial: 34076966
Drug: CPT-11 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (60 mg/m2 on days 1 and 8) every three weeks
Trial: 34076966
Drug: AMR (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR (35 mg/m2 on days 1–3) every three weeks
Trial: 34536915
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium
Trial: 35867857
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, single injection adductor canal block, plus five additional interventions: local anesthetic infiltration between the popliteal artery and capsule of the posterior knee, intraoperative intravenous dexmedetomidine and ketamine, one additional intravenous dexamethasone bolus, and two additional adductor canal block injections.
Trial: 35867857
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 39) received spinal anesthesia with intrathecal morphine, periarticular local anesthesia infiltration, intravenous dexamethasone, and a single injection adductor canal block.
Trial: 34914726
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011)
Trial: 35338847
Drug: 2.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/day of n‐3 PUFA
Trial: 35485357
Drug: HIIT (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIT (5 x 1 min at 80-95% maximal heart rate, twice weekly for 12 weeks)
Trial: 34075813
Drug: Apixaban dose
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban dose adjustment based on age, weight, and serum creatinine in NVAF.
Trial: 34799501
Drug: Dexamethasone 3
RxNorm normalized name: dexamethasone 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 3 mg
Trial: 33059195
Drug: Second-line medications
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line medications (inhaled pentamidine, dapsone, atovaquone)
Trial: 34345969
Drug: Pre‐emptive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive antibiotic treatment with clarithromycin (200 mg twice per day) during panitumumab treatment.
Trial: 33183576
Drug: Curcumin 1000
RxNorm normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1000 mg/day for 12 weeks
Trial: 32208040
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment for esophageal GISTs
Trial: 33559351
Drug: Stryphnodendron adstringens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stryphnodendron adstringens (SA) at 3000 mg/L
Trial: 33559351
Drug: Lafoensia pacari
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafoensia pacari (LP) at 300 mg/L
Trial: 33559351
Drug: Copaifera spp.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copaifera spp. (CO) at 300 mg/L
Trial: 33559351
Drug: Pterodon emarginatus
RxNorm normalized name: Malpighia emarginata seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pterodon emarginatus (PE) at 30 and 300 mg/L